BioCentury
ARTICLE | Company News

Management tracks: Axovant, Revance

May 29, 2018 10:36 PM UTC

Axovant Sciences Ltd. (NASDAQ:AXON) hired Gavin Corcoran as EVP of R&D and appointed Michael Hayden as senior scientific advisor and chairman of the neurology company’s new scientific advisory board as part of an ongoing restructuring. Corcoran is CMO at Allergan plc (NYSE:AGN), and Hayden was president of global R&D and CSO at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). Axovant also said on Tuesday that it has completed the restructuring it began in February, which saw the company reduce headcount by about 43%.

Lauren Silvernail has departed as CBO and CFO of dermatology company Revance Therapeutics Inc. (NASDAQ:RVNC) and joined medical aesthetics company Evolus Inc. (NASDAQ:EOLS) as CFO and EVP of corporate development. Revance is seeking a successor. ...